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Background  &  Aims:  In  patients  with  severe  acute  liver  dysfunction,  i.v. 
phylloquinone (vitamin K1) is oftenmay be given to exclude vitamin K deficiency, 
rather than impaired hepatic synthesis of coagulation factors alone, as the cause of the 
coagulopathy.  However,  there  have  been  no  studies  of  the  pharmacokinetics  or 
efficacy of i.v. or oral K1 in such patients. Methods: 49 adults with severe acute liver 
disease were randomised double-blind to a single 10 mg dose of i.v. or oral mixed-
micellar  K1,  or  placebo.  Serum  levels  of  phylloquinone  and  undercarboxylated 
prothrombin  (PIVKA-II)  were  assessed  before  and  after  treatment.  Results:  At 
admission, 13 patients (27%) had either low serum K1 levels or elevated PIVKA-II 
concentrations, indicative of subclinical vitamin K deficiency. In the 16 patients who 
received  i.v.  K1, there was one (6%) treatment failure (K1 rise < 10 ng/ml above 
baseline), compared with 12 of the 15 (80%) who received oral K1 (p<0.0001). One 
patient in the placebo group developed overt vitamin K deficiency. Conclusions: A 
minority of patients with severe acute liver dysfunction have subclinical vitamin K 
deficiency at the time of presentation, which is corrected by a single dose of i.v. K1. 
The  intestinal  absorption  of  mixed-micellar  K1 is  unreliable  in  adults  with  severe 
acute liver dysfunction.
INTRODUCTION
Vitamin K is an essential cofactor for the production in the liver of biologically active 
forms  of  the  coagulation  factors  II  (prothrombin),  VII,  IX,  and  X.  Its  role  is  to 
promote the conversion of certain glutamic acid residues in the protein precursors to 
γ-carboxyglutamic acid (Gla). The Gla-residues of these coagulation factors provide an efficient chelating site for calcium ions and are essential for protein-membrane 
interaction and effective haemostatic function  11. When γ-carboxylation is impaired 
because of deficiency or antagonism of vitamin K, inert precursors of vitamin K-
dependent  proteins    known  as  Proteins  Induced  by  Vitamin  K Absence  or 
Antagonism (PIVKA)  are synthesised in the liver and released into the blood 2,32,3. 
In  the  case  of  prothrombin,  specific  and  sensitive  immunoaassays  have  been 
developed which can detect small decreases in the Gla content of prothrombin before 
any  changes  occur  in  conventional  coagulation  tests  such  as  the  International 
Normalised Ratio (INR) 3-63-6.
The major dietary form of vitamin K is phylloquinone (vitamin K1; K1), which is 
derived predominantly from green leafy vegetables. Its intestinal absorption involves 
the intraluminal solubilisation of vitamin K into mixed micelles composed of bile 
salts and the products of pancreatic lipolysis. This absorption is known to be impaired 
in patients with extrahepatic biliary obstruction and severe pancreatic insufficiency 77, 
but  there  are  no  data  in  patients  with  liver  disease.  Although  impaired  hepatic 
synthesis is almost certainly the dominant factor in the development of the usually 
severe coagulopathy seen in patients with acute liver failure (ALF), such patients may 
also have multiple risk factors for vitamin K deficiency, including poor oral intake, 
severe  cholestasis  and  treatment  with  broad  spectrum  antibiotics   which  inhibit 
production  of  menaquinones  (vitamin  K2)  by  certain  intestinal  bacteria  and  their 
subsequent  ileal  absorption  88.  Consequently,  it  has  been  recommended  that 
intravenous  (i.v.)  K1 be  given  empirically  to  exclude  a  contribution  of  vitamin  K 
deficiency to the coagulopathy 99.A commonly prescribed formulation of K1 is Konakion® MM (F. Hoffmann-La Roche 
Ltd, Basle, Switzerland), which contains phylloquinone solubilised in glycocholate-
phosphatidylcholine mixed micelles. We have shown that the mixed-micellar K1 (MM 
K1) formulation is associated with a lower risk of anaphylactoid reactions after i.v. 
administration than the original Konakion, which contained the nonionic detergent 
Cremophor EL® as solubiliser  10, but that  10the intestinal absorption of MM K1 in 
infants with conjugated hyperbilirubinaemia, given as prophylaxis against vitamin K 
deficiency bleeding of the newborn, is unreliable 1112. There is no information on the 
efficiency of intestinal absorption of MM K1 in adults with liver disease. 
The  aims  of  this  randomised,  double-blind,  placebo-controlled  study  were  to:  (i) 
assess the possible contribution of vitamin K deficiency to the coagulation disorder 
found  in  patients  with  severe  acute  liver  damage,  and  (ii)  compare  the 
pharmacokinetics and efficacy of oral versus i.v. MM K1 in correcting any underlying 
vitamin K deficiency. 
PATIENTS AND METHODS
Over an eight-month period, 49 patients (24 women, 25 men; mean age 34 years, 
range 16-73 years) with, or at high risk of developing, ALF 1213, were transferred to 
the Liver Failure Unit of King’s College Hospital and enrolled into the study by one 
of two investigators (SPP and DR). As part of the eligibility criteria, all of the patients 
had an INR > 2 at admission, and none had received K1 within the preceding three 
days.  The  commonest  cause  of  acute  liver  dysfunction  was  acetaminophen 
paracetamol hepatotoxicity (n=37; 76%), followed by other drugs (ecstasy in four, paroxetine  in  one)  in  10%.  The  final  diagnoses  in  the  remainder  were  presumed 
nonA-E  viral  hepatitishepatitis  of  unknown  origin  in  two,  malignant  hepatic  liver 
infiltration in two, and one case each of acute fatty liver of pregnancy and Amanita 
phalloides poisoning. 
At  admission,  27  patients  (55%)  had  already  developed  ALF  and  were 
encephalopathic  and/or  mechanically  ventilated,  and  eight  (16%)  had  a  marked 
metabolic  acidosis  (arterial  pH  <7.3).  All  patients  were  managed  according  to  a 
standard  protocol  for  acute  liver  failure  1314.  Continuous  veno-venous 
haemodiafiltration was instituted in anuric or oliguric patients with a serum creatinine 
level of > 400 µmol/l. Intravenous N-acetylcysteine and broad-spectrum antibiotics 
were  administered  routinely.  Patients  who  developed  grade  III-IV  encephalopathy 
were  intubated  and  ventilated  electively,  and  a  nasogastric  tube  was  inserted  for 
enteral nutrition and drug administration. 
The study medications (MM K1 and placebo in identical-appearing ampoules) were 
paired and coded by the trial pharmacist, and stored at 4°C. The trial pharmacist also 
provided  the  random  allocation  sequence,  in  opaque  consecutively  numbered 
envelopes. On the day of admission, patients were randomised double-blind to: (i) 
placebo by mouth or nasogastric tube (made up to 10 ml in water) and 10 mg MM K1
i.v. (given over 1 min), (ii) 10 mg MM K1 by mouth/nasogastric tube and placebo i.v., 
or (iii) placebo/placebo. The study medications were administered by the patient’s 
nurse at 12:00 on the day of admission. The clinical status of the patients, and the 
results of standard biochemical and haematological tests, were assessed daily.Assessment of vitamin K status 
Vitamin K status was assessed from serum measurements of K1 and by a sensitive 
functional assay based on the detection of undercarboxylated species of prothrombin 
(PIVKA-II). 
Blood  samples  were  collected  before  administration  of  the  study  medications 
(baseline sample) and on the three consecutive mornings after admission, with further 
samples on days five and seven unless the patient had died or been discharged. At 
each sampling time, 10 ml of venous blood was collected into plain tubes, protected 
from light and allowed to clot at 4°C. Serum was separated by centrifugation and 
stored at -70°C.
Serum  vitamin  K1 assay:    Serum  K1  was  measured  by  high  performance  liquid 
chromatography  (HPLC)  with  electrochemical  detection  in  the  redox  mode,  as 
described previously 1415. Volumes of 0.05 ml serum were first analysed by a protocol 
designed to measure K1 concentrations in the pharmacological range (>5 ng/ml) 1415. 
If  the  level  was  <10  ng/ml  by  this  protocol,  volumes  of  0.2-0.5  ml  serum  were 
subjected to a protocol for endogenous concentrations 1415. Menaquinone-6 was used 
as the internal standard. For 0.5 ml serum extracted, the lower limit of detection was 
0.05 ng/ml. The mean intra- and inter-assay precision values (RSD %) were 3% and 
9%, respectively, for concentrations in the pharmacological range, and 5% and 10% 
for endogenous concentrations. The normal adult reference range by the same assay 
was 0.17-0.68 ng/ml (median 0.37 ng/ml) in the fasting state, and 0.15-1.55 ng/ml 
(median 0.53 ng/ml) in non-fasting subjects 1516. Serum PIVKA-II assay: Serum PIVKA-II was assayed using a conformation-specific 
monoclonal  antibody  (which  does  not  cross-react  with  fully  carboxylated  native 
prothrombin)  in  a  modification  of  a  previously  described  ELISA-based  assay  55. 
Serum PIVKA-II by immunoassay is conventionally expressed as Arbitrary Units per 
ml  (AU/ml)  since,  in  states  of  vitamin  K  deficiency,  circulating  PIVKA-II  may 
comprise  multiple  forms  of  partially  carboxylated  prothrombin  and  neither  their 
relative abundance in plasma nor their relative affinity for the antibody is known. 
Calibration is therefore made against PIVKA-II species purified from patients treated 
with oral anticoagulants. Using electrophoretic techniques, 1 AU is equivalent to 1 µg 
of  purified  PIVKA-II  55.  The  minimum  limit  of  detection  for  our  assay  was 0.15 
AU/ml. In 43 adult patients on warfarin therapy (INR > 1.5), the mean value in our 
laboratory was 40.0 AU/ml (range 6.9-99.5 AU/ml) 1617. As previously reported 1718, 
there was good agreement between the specificity of this assay and a commercial kit 
(Eitest mono-II; Eisai Co Ltd, Tokyo) which has been used widely for the detection of 
subclinical vitamin K deficiency 18-2019-21.
Statistical analysis
Data  are  expressed  as means ± SEM. Group means were compared using the the 
Student's t test (two-tailed), and differences in proportions were assessed using the χ2
test.  Pearson’s  correlation  coefficients  were  calculated  to  assess  the  strength  of 
relations  between  the  serum  K1 terminal  half-lives  (determined  by  log-linear 
regression analysis of the 24 h and 48 h data) and the severity of liver and renal 
dysfunction.
Written, informed consent was obtained from the patients or their next-of-kin. The study was approved by the Research Ethics Committee of King’s College Hospital.
RESULTS
The clinical details and laboratory values at admission of the three study groups are 
given in Table 1. The three groups were well-matched for sex, aetiology and severity 
of liver dysfunction, although patients in the oral group were somewhat younger than 
those in the other two groups (27 v 37 yr; p=0.03). The mean INR at admission was 
6.4 (range 2.0 to 15), which fell improved progressively thereafter to 4.2 at 48 h and 
1.6  at  96  h.  The  corresponding  mean  admission  values  for  serum  creatinine  and 
bilirubin were 202 (49-700) mmol/l and 154 (6-916) mmol/l, respectively, which rose 
to  peak  values  of  311  (45-752)  mmol/l  and  243  (16-886)  mmol/l  on  day  five  of 
admission. A total of 32 patients (65%) developed ALF, either before their transfer to 
King’s (n=27) or during their subsequent admission (n=5). 
Twenty-seven  of  the  49  patients  (55%)  made  a  full  recovery  with  intensive  care 
support, and eight others (16%) who fulfilled the King’s criteria for transplantation in 
ALF 1213 were transplanted on day 3-30 (median six) and later discharged. Fourteen 
other patients (29%) died 3-10 days (median six) after admission, generally due to 
chest sepsis with multiorgan failure or cerebral oedema. Ten patients in this group 
fulfilled transplant criteria, but either had medical or psychiatric contraindications to 
transplantation (n=7) or died before transplantation could be carried out (n=3).
Table 1:  
Clinical data and laboratory values at admission in the three study groups. Results are expressed as means with ranges. 
Vitamin K1 Placebo
Oral Intravenous 
No.   15 16 18
Sex   8M, 7F 7M, 9F 10M, 8F
Age (range)  27 (16-49)*† 37 (18-73)* 38 (19-73)†
Cause of ALF: AcetaminophenParacetamol Others  13 2 11 5 13 5 
Serum bilirubin (normal, 3-20 µmol/l)  186 (21-916) 153 (6-483) 131 (55-483)
Aspartate aminotransferase (10-50 IU/l)  5839 (348-22000) 3199 (25-9369) 4941 (29-
26500)
Alkaline phosphatase (30-150 IU/l)  122 (58-277) 208 (40-1665) 108 (57-196)
Gamma-glutamyl transferase (5-55 IU/l)  78 (31-190) 167 (18-1249) 78 (23-174)
International Normalised Ratio (0.7-1.2) 6.2 (2.8-12.1) 6.0 (2.0-15) 6.9 (2.0-15)
*p=0.03 oral v i.v. group. †p=0.03 oral v placebo group. There were no significant 
differences between the three groups with respect to the other variables.
Serum vitamin K1
Mean baseline serum concentrations of K1 were similar in the three groups, being 1.6
±0.4 ng/ml (range, 0.2-6.5 ng/ml) in the i.v. MM K1 group, 2.4±0.8 ng/ml (0.1-10.0 
ng/ml)  in  those  given  MM  K1 orally,  and 2.2±0.08 ng/ml (0.03-6.5 ng/ml) in the 
placebo group (NS). Three of the 49 patients (6%) had pretreatment serum K1 levels 
below the normal limit of 0.15 ng/ml (one in the oral group and two in the placebo 
group), and a further two patients (both in the placebo group) developed low levels 
within 48 h after admission despite clinical improvement in both patients. In those 
given placebo, there was a progressive fall in mean serum K1 concentrations with time, from 2.2±0.08 ng/ml (0.03-6.5 ng/ml) at admission, to 1.8 ng/ml (0.1-4.5 ng/ml) 
at 48 h, 1.0 ng/ml (0.1-2.7 ng/ml) at five days, and to 0.7 ng/ml (0.5-1.3 ng/ml) on day 
seven. 
Individual and mean serum concentrations of K1 in the two supplemented groups, 
expressed on a logarithmic scale, are shown in Fig. 1. At 24 h after i.v. MM K1, the 
peak serum K1 concentrations was 91.5±39.2 ng/ml (range 7.2-650 ng/ml), compared 
with 17.2±8.4 ng/ml (range 0.3-91.8 ng/ml) after oral MM K1 (p=0.08 i.v. v oral). 
When  treatment  failure  was  defined  as  an  incremental  K1 rise  <  10  ng/ml,  one 
instance was recorded in the 16 patients (6%) given i.v. MM K1, compared with 12 
treatment failures in the 15 (80%) who received oral MM K1 (p<0.0001). Figure 1 Serum  concentrations  of  vitamin  K1  after  oral  or  i.v.  mixed-micellar 
vitamin K1. Serum PIVKA-II
At  admission,  nine  of  the  49  patients  (18%)  had  mildly  raised  PIVKA-II 
concentrations of 0.15-0.91 AU/ml, consistent with subclinical vitamin K deficiency. 
These elevated levels fell by at least 50% within 48 h in two of the four patients given 
oral MM K1, in both of the patients given i.v. MM K1, and in none of the three in the 
placebo group (Fig. 2). In the two patients from the oral group whose serum PIVKA-II 
levels rose further after vitamin K, the maximum incremental K1 rise of 2.3 ng/ml 
indicated poor intestinal absorption in both.
Two other patients had markedly raised PIVKA-II levels (> 10 AU/ml and 8 AU/ml), 
which  were  in  the  same  range  as  that  found  in  patients  with  overt  vitamin  K 
deficiency or during oral anticoagulation therapy. One of these patients was given i.v. 
K1, and the PIVKA-II level fell from > 10 AU/ml to 3.3 AU/ml after 48 h (and to 0.50 
AU/ml on day 7), with a corresponding fall improvement in the INR from 2.2 to 1.0. 
The  other  patient  was  in  the  placebo  group,  and  the  PIVKA-II  level  rose  from  8 
AU/ml  to  >  10  AU/ml  at  all  subsequent  time  points  between  24  h  and  7  days. 
Following an initial fall improvement in the INR from 2.6 at admission to 1.3 at 48 h, 
the INR again increased to 2.6 on day 7 despite improving liver function tests, and 
subsequently returned to normal 48 h after the patient was removed from the trial and 
given i.v. MM K1.Figure 2 Serum  concentrations  of  undercarboxylated  prothrombin  (PIVKA-II; logarithmic scale) before and 48 h after mixed-micellar vitamin K1 or 
placebo. The dashed horizontal line at 0.15 AU/ml represents the upper 
limit of normal. 
Vitamin K1 pharmacokinetics
In the 15 patients (12 in the i.v. group) with peak incremental serum K1 levels > 10 
ng/ml in whom half-lives could be determined, the mean serum terminal half-life of 
MM K1 was 25.3±3.7 h (range, 6.6-55.9 h). Seventeen of the patients (35%) required 
renal support during their admission, with continuous veno-venous haemodiafiltration 
in 15 and haemodialysis in two. Amongst the patients requiring renal support, the 
mean serum K1 half-life was 26.3±6.7 h, compared with a half-life of 24.7±4.6 h in 
those  with  preserved  renal  function  (NS).  There  were  no  significant  correlations 
between serum K1 half-life and admission or peak serum creatinine concentrations, 
severity of liver disease (as assessed by the INR and serum bilirubin) or need for 
ventilation.
DISCUSSION
In  severe  acute  liver  disease,  there are reductions in the plasma concentrations of 
several coagulation proteins, including the procoagulant vitamin K-dependent factors 
II, VII, IX and X and the anticoagulant protein C 9,219,22. The hepatic synthesis of these 
vitamin  K-dependent  factors  differs  from  other  coagulation  factors  in  that  their 
functional activity is also dependent on the integrity of the microsomal γ-glutamyl 
carboxylation system, which converts the inactive protein precursors to their active zymogens, with a Thus,reduced ratio of functional to antigenic levels of prothrombin 
being a hallmark of an impaired carboxylation resulting in the hepatic secretion of 
non-functional  PIVKA-II  22,2324.  In  ALF,  it  has  been  commonly  assumed  that  the 
reduced levels of prothrombin (and other vitamin K-dependent proteins) are due to 
impaired hepatic protein synthesis 2223. However, Kerr et al 2425 showed recently that 
the factors that fall to the lowest levels in ALF are those which are directly activated 
after tissue factor generation  pointing to a tissue factor-initiated consumption of 
factors II, V, VII and X (but not factor IX) as a major cause of their depletion in ALF. 
The present study has shown that over a quarter of patients with severe acute liver 
dysfunction have subclinical vitamin K deficiency at presentation which, if untreated, 
may progress to overt vitamin K deficiency with a raised INR and bleeding tendency. 
The PIVKA-II analyses showed that 11/49 patients (22%) presented with a functional 
defect of prothrombin γ-carboxylation. In most, PIVKA-II was mildly raised (0.15-1.0 
AU/ml),  consistent  with  subclinical  vitamin  K  deficiency,  but  in  two  patients  the 
PIVKA-II was in the range found in warfarin-anticoagulated patients (>7.0 AU/ml), 
indicating that a component of their raised INR was due to overt vitamin K deficiency. 
A smaller proportion of 3/49 patients (6%) had a low pre-treatment serum K1 (<0.15 
ng/ml), suggestive of a low tissue vitamin K status. As in previous reports 20,2521,30, we 
did not detect an association between baseline serum K1 and PIVKA-II levels. Serum 
K1 concentrations at admission varied widely, presumably related in part to variations 
in dietary intake 2635 and inter-individual differences between circulating vitamin K 
and liver stores (which may include bacterial menaquinones; K2 vitamins). Another 
possible reason for the lack of association between serum K1 and PIVKA-II is that 
some patients may have received vitamin K more than three days before transfer to King’s College Hospital. At admission, 10 (20%) had K1 levels above the upper limit 
of the non-fasting range (1.6 ng/ml). PIVKA-II has a long terminal half-life and may 
remain detectable in plasma for several days after correction of vitamin K deficiency.
To the authors’ knowledge, this is the first detailed study of vitamin K status in severe 
acute liver dysfunction and the first placebo-controlled study of vitamin K prophylaxis 
using either the intravenous or oral route. Under normal physiological conditions, 40-
70% of an oral dose of K1 is absorbed from the jejunum and ileum of the upper 
intestine and as for other fat-soluble vitamins and highly lipid-soluble nutrients, the 
intraluminal phase of absorption involves the solubilisation of K1 into mixed micelles 
77.  In  the  present  study,  we  found  that  only  20%  of  patients  given  the  oral  MM 
formulation developed an incremental serum K1 rise ≥ 10 ng/ml at 24 h, compared 
with all but one (94%) of those given i.v. K1. 
In the patients in whom serum half-lives could be estimated, the mean K1 terminal 
half-life of 25.3 ± 3.7 h was about approximaely twofold longer than that found in 
subjects with normal hepatic function given pharmacological doses of the same MM 
preparation 2738. This finding of a prolonged terminal half-life in patients with severe 
acute  liver  dysfunction  is  not  unexpected,  since  tracer  experiments  with  labelled 
phylloquinone in normal individuals have shown that a sizable fraction of a single 
dose is rapidly catabolised in the liver, with at least 40-50% excreted in the faeces via 
the bile and 20% excreted in the urine within three days 77. 
In summary, over a quarter of our patients presenting with severe acute liver damage 
had evidence of subclinical K1 deficiency at admission, which was corrected by a single dose of i.v. MM K1. Intestinal absorption of MM K1 in these patients was 
unreliable,  so  that  there  is  no  rationale  to  change  our  current  practice  of 
recommending  i.v.  K1 to  patients  with  severe  liver  disease  and  an  associated 
coagulopathy. Based on the findings of a markedly prolonged serum K1 half-life in 
these patients, a single dose of 10 mg K1 given i.v. appears to be sufficient to maintain 
supraphysiological vitamin K blood levels for at least a week. 
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